Recent improvement in survival of patients with multiple myeloma: variation by ethnicity

References

• Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521–2526.
   PubMed Web of Science ®Google Scholar
• Brenner H, Gondos A, Pulte D. Expected survival of patients diagnosed with multiple myeloma in 2006–2010. Haematologica 2009;94:270–275.
   PubMed Web of Science ®Google Scholar
• Turesson I, Velez R, Kristinsson SY, et al. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 2010;28:830–834.
   PubMed Web of Science ®Google Scholar
• Wong SL, Gu N, Banerjee M, et al. The impact of socioeconomic status on cancer care and survival. J Clin Oncol 2011;29(Suppl.): Abstract 6004.
   Google Scholar
• Macartney S, Bishaw A, Fontenot K. Poverty rates for selected detailed race and Hispanic groups by state and place: 2007–2011. American Community Survey Briefs; February 2013. Available from:www.census.gov/prod/2013pubs/acsbr11-17.pdf
   Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program. Research Data (1973–2008), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011, based on the November 2010 submission. Available from: www.seer.cancer.gov
   Google Scholar
• Kaya H, Peressini B, Jawed I, et al. Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. Int J Hematol 2012;95:64–70.
   PubMed Web of Science ®Google Scholar
• Mariotto A, Capocaccia R, Verdecchia A, et al. Projecting SEER cancer survival rates to the US: an ecological regression approach. Cancer Causes Control 2002;13:101–111.
   PubMed Web of Science ®Google Scholar
• Bone Marrow and Cord Blood Donation and Transplantation. Last updated: 18 May 2011. Available from: http://bloodcell.transplant.hrsa.gov/index.htm
   Google Scholar
• Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 1961;6:101–121.
   PubMedGoogle Scholar
• Henson DE, Ries LA. The relative survival rate. Cancer 1995;76:1687–1688.
   PubMed Web of Science ®Google Scholar
• Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note No. 10. Bethesda, MD: National Cancer Institute; 1959.
   Google Scholar
• Arias E. United States life tables, 2000. Natl Vital Stat Rep 2002;51:1–39.
   PubMedGoogle Scholar
• Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer 1996;78:2004–2010.
   PubMed Web of Science ®Google Scholar
• Brenner H, Gefeller O, Hakulinen T. Period analysis for “up-to-date” cancer survival data: empirical evaluation, computational realisation and applications. Eur J Cancer 2004;40:326–335.
   PubMed Web of Science ®Google Scholar
• Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011;377: 127–138.
   PubMed Web of Science ®Google Scholar
• Brenner H, Hakulinen T. Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol 2002;20: 826–832.
   PubMed Web of Science ®Google Scholar
• Brenner H. and Hakulinen T. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol 2006;164:689–696.
   PubMed Web of Science ®Google Scholar
• van de Schans SA, Gondos A, van Spronsen DJ, et al. Improving relative survival, but remaining differences in survival for non-Hodgkin's lymphoma across Europe and the United States from 1990 to 2004. J Clin Oncol 2011;29:192–199.
   PubMed Web of Science ®Google Scholar
• Pulte D, Gondos A, Brenner H. Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States 1990–2004. J Natl Cancer Inst 2008;100:1301–1309.
   PubMed Web of Science ®Google Scholar
• Corazziari I, Quinn M, Capocacci R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 2004;40:2307–2316.
   PubMed Web of Science ®Google Scholar
• Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med 2004;23:51–64.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 851:1860–1873.
   Web of Science ®Google Scholar
• Hadley J. Sicker and poorer-the consequences of being uninsured: a review of research on the relationship between health insurance, medical care use, health, work, and income. Med Care Res Rev 2003;60:3S–75S.
   PubMed Web of Science ®Google Scholar
• Health, United States, 2012: with special feature on emergency care. Hyattsville, MD: National Center for Health Statistics; 2013.
   Google Scholar
• Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 2010;116:5501–5506.
   PubMed Web of Science ®Google Scholar
• Greenberg AJ, Vachon CM, Rajkumar SV. Disparities in the prevalence, pathogenesis, and progression of monoclonal gammopathy of undetermined significance and mulitple myeloma bewtwen blacks and whites. Leukemia 2012;26:609–614.
   PubMed Web of Science ®Google Scholar
• Joshua TV, Rizzo DJ, Yhang MJ, et al. Access to hematopoietic stem cell transplantation: effect of race and sex. Cancer 2010;116: 3469–3476.
   PubMed Web of Science ®Google Scholar
• Hari PN, Majhail NS, Yhang MJ, et al. Race and outcomes of autologous hematopoietic cell tranplantations for multiple myeloma. Biol Blood Marrow Transplant 2010;16:395–402.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
   PubMed Web of Science ®Google Scholar
• Abou-Jawde RM, Baz R, Walker E, et al. The role of race, socioeconomic status, and distance traveled on outcomes of African-American patients with multiple myeloma. Haematologica 2006;91:1410–1413.
   PubMed Web of Science ®Google Scholar
• Modiano MR, Villar-Werstler P, Crowley J, et al. Evaluation of race as a prognostic factor in multiple myeloma. J Clin Oncol 1996; 14:974–977.
   PubMed Web of Science ®Google Scholar
• Savage D, Lindenbaum J, Van Ryzin J, et al. Race, poverty, and survival in multiple myeloma. Cancer 1984;54:3085–3094.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francis du Myeloma. N Engl J Med 1996:335:91–97.
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565–1571.
   PubMed Web of Science ®Google Scholar
• Dimopoulous M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–2132.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609–2617.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisode chemotherapy plus thalidomide compared to melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825–831.
   PubMed Web of Science ®Google Scholar
• Saraf S, Patel PR, Ozer H, et al. Favorable responses to novel agents for multiple myeloma in African American patients. Blood 2011;118(Suppl. 1): Abstract 4213.
   Google Scholar
• Richardson PG, Barlogie B, Berenson J, et al. Clinical factors predictive of outcome with bortezomib in patients with relapse, refractory multiple myeloma. Blood 2005;106:2977–2981.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Tobinai K, Ogura M, et al. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Cancer Sci 2008;99:140–144.
   PubMed Web of Science ®Google Scholar
• US Census Bureau Migration by race and Hispanic origin: 1995 to 2000 Census 2000 Special Reports Issued 0ctober, 2003. Available from: www.census.gov/population/hispanic/publications/
   Google Scholar
• Grieco EM, Acosta YD, de la Cruz GP, et al. The foreign-born population in the United States: 2010. American Community Survey Reports. Issued May 2012. Available from: www.census.gov/prod/2012pubs/acs-19.pdf
   Google Scholar
• DeNavas-Walt C, Proctor BD, Smith JC. US Census Bureau, Current Population Reports, P60-238. Income, poverty, and health insurance coverage in the United States: 2009. Washington, DC: US Government Printing Office; 2010.
   Google Scholar
• Huang K, Carrasquillo O. The role of citizenship, employment, and socioeconomic characteristics in health insurance coverage among Asian subgroups in the United States. Med Care 2008:46:1093–1098.
   PubMed Web of Science ®Google Scholar
• Fuller-Thomson E, Noack AM, George U. Health decline among recent immigrants to Canada: findings from a nationally-representative longitudinal survey. Can J Public Health 2011;102:273–280.
   PubMed Web of Science ®Google Scholar
• Hacker K, Chu J, Leung C, et al. The impact of immigration and customs enforcement on immigrant health: perceptions of immigrants in Everett, Massachusetts, USA. Soc Sci Med 2011;73:586–594.
   PubMed Web of Science ®Google Scholar
• Kullgren JT. Restrictions on undocumented immigrants’ access to health services: the public health implications of welfare reform. Am J Public Health 2003;93:1630–1633.
   PubMed Web of Science ®Google Scholar